<?xml version='1.0' encoding='utf-8'?>
<document id="24366297"><sentence text="Pazopanib exposure decreases as a result of an ifosfamide-dependent drug-drug interaction: results of a phase I study."><entity charOffset="0-9" id="DDI-PubMed.24366297.s1.e0" text="Pazopanib" /><entity charOffset="47-57" id="DDI-PubMed.24366297.s1.e1" text="ifosfamide" /><pair ddi="false" e1="DDI-PubMed.24366297.s1.e0" e2="DDI-PubMed.24366297.s1.e0" /><pair ddi="false" e1="DDI-PubMed.24366297.s1.e0" e2="DDI-PubMed.24366297.s1.e1" /></sentence><sentence text="The vascular endothelial growth factor receptor (VEGFR) pathway plays a pivotal role in solid malignancies and is probably involved in chemotherapy resistance" /><sentence text=" Pazopanib, inhibitor of, among other receptors, VEGFR1-3, has activity as single agent and is attractive to enhance anti-tumour activity of chemotherapy"><entity charOffset="1-10" id="DDI-PubMed.24366297.s3.e0" text="Pazopanib" /></sentence><sentence text=" We conducted a dose-finding and pharmacokinetic (PK)/pharmacodynamics study of pazopanib combined with two different schedules of ifosfamide"><entity charOffset="80-89" id="DDI-PubMed.24366297.s4.e0" text="pazopanib" /><entity charOffset="131-141" id="DDI-PubMed.24366297.s4.e1" text="ifosfamide" /><pair ddi="false" e1="DDI-PubMed.24366297.s4.e0" e2="DDI-PubMed.24366297.s4.e0" /><pair ddi="false" e1="DDI-PubMed.24366297.s4.e0" e2="DDI-PubMed.24366297.s4.e1" /></sentence><sentence text="" /><sentence text="In a 3+3+3 design, patients with advanced solid tumours received escalating doses of oral pazopanib combined with ifosfamide either given 3 days continuously or given 3-h bolus infusion daily for 3 days (9 g m(-2) per cycle, every 3 weeks)"><entity charOffset="90-99" id="DDI-PubMed.24366297.s6.e0" text="pazopanib" /><entity charOffset="114-124" id="DDI-PubMed.24366297.s6.e1" text="ifosfamide" /><pair ddi="false" e1="DDI-PubMed.24366297.s6.e0" e2="DDI-PubMed.24366297.s6.e0" /><pair ddi="false" e1="DDI-PubMed.24366297.s6.e0" e2="DDI-PubMed.24366297.s6.e1" /></sentence><sentence text=" Pharmacokinetic data of ifosfamide and pazopanib were obtained"><entity charOffset="25-35" id="DDI-PubMed.24366297.s7.e0" text="ifosfamide" /><entity charOffset="40-49" id="DDI-PubMed.24366297.s7.e1" text="pazopanib" /><pair ddi="false" e1="DDI-PubMed.24366297.s7.e0" e2="DDI-PubMed.24366297.s7.e0" /><pair ddi="false" e1="DDI-PubMed.24366297.s7.e0" e2="DDI-PubMed.24366297.s7.e1" /></sentence><sentence text=" Plasma levels of placental-derived growth factor (PlGF), vascular endothelial growth factor-A (VEGF-A), soluble VEGFR2 (sVEGFR2) and circulating endothelial cells were monitored as biomarkers" /><sentence text="" /><sentence text="Sixty-one patients were included" /><sentence text=" Pazopanib with continuous ifosfamide infusion appeared to be safe up to 1000 mg per day, while combination with bolus infusion ifosfamide turned out to be too toxic based on a variety of adverse events"><entity charOffset="1-10" id="DDI-PubMed.24366297.s11.e0" text="Pazopanib" /><entity charOffset="27-37" id="DDI-PubMed.24366297.s11.e1" text="ifosfamide" /><entity charOffset="128-138" id="DDI-PubMed.24366297.s11.e2" text="ifosfamide" /><pair ddi="false" e1="DDI-PubMed.24366297.s11.e0" e2="DDI-PubMed.24366297.s11.e0" /><pair ddi="false" e1="DDI-PubMed.24366297.s11.e0" e2="DDI-PubMed.24366297.s11.e1" /><pair ddi="false" e1="DDI-PubMed.24366297.s11.e0" e2="DDI-PubMed.24366297.s11.e2" /><pair ddi="false" e1="DDI-PubMed.24366297.s11.e1" e2="DDI-PubMed.24366297.s11.e1" /><pair ddi="false" e1="DDI-PubMed.24366297.s11.e1" e2="DDI-PubMed.24366297.s11.e2" /></sentence><sentence text=" Ifosfamide-dependent decline in pazopanib exposure was observed"><entity charOffset="1-11" id="DDI-PubMed.24366297.s12.e0" text="Ifosfamide" /><entity charOffset="33-42" id="DDI-PubMed.24366297.s12.e1" text="pazopanib" /><pair ddi="false" e1="DDI-PubMed.24366297.s12.e0" e2="DDI-PubMed.24366297.s12.e0" /><pair ddi="false" e1="DDI-PubMed.24366297.s12.e0" e2="DDI-PubMed.24366297.s12.e1" /></sentence><sentence text=" Increases in PlGF and VEGF-A with concurrent decline in sVEGFR2 levels, consistent with pazopanib-mediated VEGFR2 inhibition, were observed after addition of ifosfamide"><entity charOffset="89-98" id="DDI-PubMed.24366297.s13.e0" text="pazopanib" /><entity charOffset="159-169" id="DDI-PubMed.24366297.s13.e1" text="ifosfamide" /><pair ddi="false" e1="DDI-PubMed.24366297.s13.e0" e2="DDI-PubMed.24366297.s13.e0" /><pair ddi="false" e1="DDI-PubMed.24366297.s13.e0" e2="DDI-PubMed.24366297.s13.e1" /></sentence><sentence text="" /><sentence text="Continuous as opposed to bolus infusion ifosfamide can safely be combined with pazopanib"><entity charOffset="40-50" id="DDI-PubMed.24366297.s15.e0" text="ifosfamide" /><entity charOffset="79-88" id="DDI-PubMed.24366297.s15.e1" text="pazopanib" /><pair ddi="false" e1="DDI-PubMed.24366297.s15.e0" e2="DDI-PubMed.24366297.s15.e0" /><pair ddi="false" e1="DDI-PubMed.24366297.s15.e0" e2="DDI-PubMed.24366297.s15.e1" /></sentence><sentence text=" Ifosfamide co-administration results in lower exposure to pazopanib, not hindering biological effects of pazopanib"><entity charOffset="1-11" id="DDI-PubMed.24366297.s16.e0" text="Ifosfamide" /><entity charOffset="59-68" id="DDI-PubMed.24366297.s16.e1" text="pazopanib" /><entity charOffset="106-115" id="DDI-PubMed.24366297.s16.e2" text="pazopanib" /><pair ddi="false" e1="DDI-PubMed.24366297.s16.e0" e2="DDI-PubMed.24366297.s16.e0" /><pair ddi="false" e1="DDI-PubMed.24366297.s16.e0" e2="DDI-PubMed.24366297.s16.e1" /><pair ddi="false" e1="DDI-PubMed.24366297.s16.e0" e2="DDI-PubMed.24366297.s16.e2" /><pair ddi="false" e1="DDI-PubMed.24366297.s16.e1" e2="DDI-PubMed.24366297.s16.e1" /><pair ddi="false" e1="DDI-PubMed.24366297.s16.e1" e2="DDI-PubMed.24366297.s16.e2" /></sentence><sentence text=" Recommended dose of pazopanib for further studies combined with 3 days continuous ifosfamide (9 g m(-2) per cycle, every 3 weeks) is 800 mg daily"><entity charOffset="21-30" id="DDI-PubMed.24366297.s17.e0" text="pazopanib" /><entity charOffset="83-93" id="DDI-PubMed.24366297.s17.e1" text="ifosfamide" /><pair ddi="false" e1="DDI-PubMed.24366297.s17.e0" e2="DDI-PubMed.24366297.s17.e0" /><pair ddi="false" e1="DDI-PubMed.24366297.s17.e0" e2="DDI-PubMed.24366297.s17.e1" /></sentence><sentence text="" /></document>